Researchers sought to assess the incidence of thrombotic complications in the second wave of patients with COVID-19, how many patients had diagnostic imaging for these complications, overall mortality, and then compared these outcomes with the first wave.
A team of researchers conducted a meta-analysis to determine the variation in incidence of venous thromboembolism following resection for colorectal cancer.
Results of a rodent model show that fibrin-specific core-shell nanogels with a tissue-type plasminogen activator warrants more study as a treatment for patients with DIC.
Immigrants may be at a lower risk for mortality after ischemic stroke compared with long-term residents, but the risk for vascular event recurrence was similar in both populations.
A team of investigators conducted an observational study to evaluate the incidence of venous thromboembolism and whether early anticoagulation affected survival in critically ill patients with COVID-19.
A novel assay for evaluating ADAMTS13 activity may be both fast and reliable for the diagnosis of thrombotic thrombocytopenic purpura (TTP), according to the results of a study published in Research and Practice in Thrombosis and Hemostasis. A thrombotic microangiopathy that can be life-threatening, TTP can be diagnosed only through measurement of ADAMTS13 activity, which…
A single-institution chart review of patients with TTP showed evidence that they may be at higher risk for VTE; therefore, there may be a need to implement VTE thromboprophylaxis earlier for hospitalized patients.
A letter to the editor drew attention to the increased risk of thrombotic disorder for patients with severe COVID-19, which seems to occur by interacting with the von Willebrand Factor-ADAMTS13 axis.
A team of researchers sought to determine the frequency of and risk factors associated with ischemic stroke in patients with immune thrombotic thrombocytopenic purpura.
Researchers identified predictive markers — including plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA — for the pathogenesis of and prognosis for patients with iTTP.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Among pediatric patients with cerebral venous thrombosis, treatment with rivaroxaban or standard anticoagulants resulted in a similarly reduced risk for recurrent VTE or bleeding.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
Study results confirmed that dabigatran has comparable efficacy and safety as standard of care heparin or vitamin K antagonists for acute VTE in children.
A novel diagnostic algorithm was able to safely rule out DVT in patients visiting an emergency department, thereby reducing the need for ultrasound imaging.
A retrospective analysis showed similar outcomes for cyclophosphamide as seen with rituximab in treatment of immune thrombotic thrombocytopenic purpura.
A retrospective analysis shows that real-world outcomes with caplacizumab for thrombotic thrombocytopenic purpura are similar to clinical trial results.
Caplacizumab with therapeutic plasma exchange and immunosuppression appears to prevent unfavorable clinical outcomes in patients with immune-mediated TTP.
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
A single-center study in Canada found a point prevalence of Gaucher disease of 0.5% among Canadian patients referred to a hematologist for thrombocytopenia.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
A team of researchers evaluated the current health system-wide practices and protocols associated with the administration of DOACs in anticoagulation clinics.